Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.56 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950083 | 1.00 | ADORA2A (0.59) | ADORA2AADORA3ADORA2BADORA1HSP90B1 | |
| SCHEMBL12359680 | 1.00 | ADORA2A (0.59) | ADORA2AADORA3ADORA2BADORA1HSP90B1 | |
| SCHEMBL12359679 | 1.00 | ADORA2A (0.59) | ADORA2AADORA3ADORA2BADORA1HSP90B1 | |
| SCHEMBL12547695 | 1.00 | ADORA2A (0.59) | ADORA2AADORA3ADORA2BADORA1HSP90B1 | |
| SCHEMBL12359633 | 1.00 | ADORA2A (0.59) | ADORA2AADORA3ADORA2BADORA1HSP90B1 | |
| SCHEMBL13020463 | 1.00 | ADORA2A (0.59) | ADORA2AADORA3ADORA2BADORA1HSP90B1 | |
| SCHEMBL12359683 | 0.91 | ADORA2A (0.62) | ADORA2AADORA3ADORA2BADORA1HSP90B1 | |
| SCHEMBL12547506 | 0.91 | ADORA2A (0.64) | ADORA2AADORA3ADORA2BADORA1HSP90B1 | |
| SCHEMBL12359573 | 0.91 | ADORA2A (0.64) | ADORA2AADORA3ADORA2BADORA1HSP90B1 | |
| SCHEMBL12359684 | 0.91 | ADORA2A (0.61) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | The Regents of the University of Colorado, a body corporation (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | The Regents of the University of Colorado, a body corporation (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA3 1/4885ADORA2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.